CCR7 Antibody (SR36-04)

Western Blot: CCR7 Antibody (SR36-04) [NBP2-67324] - Analysis of CCR7 on different lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1:5,000 dilution was used for 1 hour at room temperature. Positive control: Lane 1: Jurkat cell lysateLane 2: MCF-7 cell lysate Lane 3: PC-12 cell lysate Lane 4: Daudi cell lysate

Immunocytochemistry/Immunofluorescence: CCR7 Antibody (SR36-04) [NBP2-67324] - Gross and histological appearance of lung excised from 13 weeks of age PyMT transgenic females. CRE treated PyMT transgenic females showed decreased frequency of mammary tumor-derived lung metastases. Immunohistochemistry staining against Ccr7 in lung tissues was done and representative images of tissue sections from each group were taken at 200X and 40X magnification. Scale bars = 50um. Histogram data was presented as mean +/- SEM. * p < 0.05 vs. control. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/2072-6643/11/2/410), licensed under a CC-BY license.

Immunohistochemistry-Paraffin: CCR7 Antibody (SR36-04) [NBP2-67324] - Analysis of paraffin-embedded human tonsil tissue using anti-CCR7 antibody. Counter stained with hematoxylin.

Western Blot: CCR7 Antibody (SR36-04) [NBP2-67324] - Gross and histological appearance of lung excised from 13 weeks of age PyMT transgenic females. CRE treated PyMT transgenic females showed decreased frequency of mammary tumor-derived lung metastases. Level of Ccr7 protein in lung tissues was analyzed by Western blot. Gapdh was used as an internal control. * p < 0.05 vs. control. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/2072-6643/11/2/410), licensed under a CC-BY license.

Immunocytochemistry/Immunofluorescence: CCR7 Antibody (SR36-04) [NBP2-67324] - Staining CCR7 in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.

Immunocytochemistry/Immunofluorescence: CCR7 Antibody (SR36-04) [NBP2-67324] - Staining CCR7 in MCF-7 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.

Immunohistochemistry-Paraffin: CCR7 Antibody (SR36-04) [NBP2-67324] - Analysis of paraffin-embedded human spleen tissue using anti-CCR7 antibody. Counter stained with hematoxylin.

Western Blot: CCR7 Antibody (SR36-04) [NBP2-67324] - Downregulation of CCR7 gene by siRNA inhibits gene expression of MMP9, c-FOS, c-JUN and CCL21 in vitro. Western blot of proteins extracted from MCF7 cell against CCR7 and GAPDH. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/2072-6643/11/2/410), licensed under a CC-BY license.

Western Blot: CCR7 Antibody (SR36-04) [NBP2-67324] - Curcumae radix extract treatment exhibited anti-metastatic effects on primary tumor of MMTV-PyMT transgenic mouse. (A) Quantitative analysis of real-time PCR was done using genes associated with breast cancer metastasis. The expression levels of Ccr7, c-Fos, Mmp9, Ccl21, & Ccl19 were determined by qRT-PCR. The Hprt gene was used as input control, respectively, * p < 0.05 & ** p < 0.005 vs. control. (B) Western blot of proteins extracted from tumor tissues in the PyMT transgenic model against Ccr7 & Gapdh. Histogram data was presented as mean ± SEM. * p < 0.05 vs. control. (C) Western blot of proteins extracted from tumor tissues against Phosphorylated Akt, Phosphorylated Ampk, Her2, ERalpha, Gapdh & beta -actin. (D) Quantitative analysis of real time PCR was done by using genes associated with apoptosis. The expression levels of Jun, Akt, & Tnf were determined by qRT-PCR. Data are representative of three independent experiments & are expressed as the mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30781353), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

• Reactivity: Hu, Mu, Rt
• Applications: WB, ICC/IF, IHC, IP, Mycoplasma
• Clone: SR36-04
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Concentration: 1 mg/ml

CCR7 Antibody (SR36-04) Summary

• Description: Novus Biologicals Rabbit CCR7 Antibody (SR36-04) (NBP2-67324) is a recombinant monoclonal antibody validated for use in IHC, WB, ICC/IF and IP. Anti-CCR7 Antibody: Cited in 2 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Synthetic peptide within Human CCR7 aa 13-62 / 378. (SwissProt: P32248 Human; SwissProt: P47774 Mouse; Unigene:229736 Rat)
• Localization: Cell membrane
• Source: HEK293
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: CCR7
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1:200
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin 1:200
  • Immunoprecipitation
  • Knockdown Validated
  • Western Blot 1:500-1:5000
• Application Notes: IP-Assay-dependent

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: TBS (pH7.4), 0.05% BSA, 40% Glycerol
• Preservative: 0.05% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for CCR7 Antibody (SR36-04)

• BLR2
• BLR2C-C chemokine receptor type 7
• C-C CKR-7
• CC-CKR-7
• CCR7
• CCR-7
• CD197 antigen
• CD197
• CDw197
• CDw197CC chemokine receptor 7
• chemokine (C-C motif) receptor 7
• CMKBR7
• CMKBR7chemokine (C-C) receptor 7
• EBI1
• EBI1EBV-induced G protein-coupled receptor 1
• EBV-induced G-protein coupled receptor 1
• Epstein-Barr virus induced gene 1
• Epstein-Barr virus induced G-protein coupled receptor
• Epstein-Barr virus-induced G-protein coupled receptor 1
• EVI1
• lymphocyte-specific G protein-coupled peptide receptor
• MIP-3 beta receptor

Background

Chemokine receptor 7 (CCR7) is a G-protein coupled receptor (GPCR) that binds chemokine ligand 19 (CCL19) and chemokine ligand 21 (CCL21) and, together, this receptor-ligand interaction functions in inflammatory and adaptive immune response (1,2). The CCR7 protein contains 7-transmembrane spanning alpha helices and is 378 amino acids (aa) in length, with a theoretical molecular weight of 42.8 kDa (3,4). CCR7 is expressed on several cells within the immune system, including naive T cells, central memory T cells, regulatory T cells, naive B cells, a subset of double negative and single positive thymocytes, and mature dendritic cells (DCs) (1, 3).

The primary role of the CCR7/CCL19/CCL21 chemokine signaling axis is homing T cells and DCs to lymph nodes and lymphoid tissues to initiate an immune response (1,2,5,6). In the context of cancer, the CCR7 signaling axis appears to have two opposing roles (2). Downregulation of CCR7 on CD8+ T cells contributes to effector cell migration and anti-cancer activities via cytotoxic tumor-infiltrating lymphocytes (2). However, upregulation of CCR7 by cancer cells can result in cancer cell migration and metastasis (2). Overexpression of CCR7 has been implicated in a variety of cancers including breast, cervical, gastric, head and neck cell carcinoma, and prostate (1,2,7). Studies in breast cancer have found that hypoxia increases CCR7 expression, and this activation can affect cancer cell invasion, extravasation, proliferation, angiogenesis, and metastasis through induction of multiple signaling transduction pathways such as PI3K/AKT, MAPK, and JAK/STAT (5,7).

Given its important role in inflammation and immune response, several strategies have been employed to target the CCR7 signaling axis for cancer immunotherapy (2). Some cancer immunotherapies under investigation include intra-tumoral administration of CCL19 and CCL21, introduction of patient-derived cells transfected to express CCR7 or its ligands, and vaccines (2). Further interrogation of CCR7/CCL19/CCL21 signaling axis is required to develop better therapeutic strategies for cancer treatment.

References:

1. Comerford, I., Harata-Lee, Y., Bunting, M. D., Gregor, C., Kara, E. E., & McColl, S. R. (2013). A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. Cytokine & growth factor reviews, 24(3), 269-283. https://doi.org/10.1016/j.cytogfr.2013.03.001

2. Salem, A., Alotaibi, M., Mroueh, R., Basheer, H. A., & Afarinkia, K. (2021). CCR7 as a therapeutic target in Cancer. Biochimica et biophysica acta. Reviews on cancer, 1875(1), 188499. https://doi.org/10.1016/j.bbcan.2020.188499

3. Yan, Y., Chen, R., Wang, X., Hu, K., Huang, L., Lu, M., & Hu, Q. (2019). CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention. Frontiers in cell and developmental biology, 7, 212. https://doi.org/10.3389/fcell.2019.00212

4. Uniprot (P32248)

5. Korbecki, J., Grochans, S., Gutowska, I., Barczak, K., & Baranowska-Bosiacka, I. (2020). CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. International journal of molecular sciences, 21(20), 7619. https://doi.org/10.3390/ijms21207619

6. Sanchez-Sanchez, N., Riol-Blanco, L., & Rodriguez-Fernandez, J. L. (2006). The multiple personalities of the chemokine receptor CCR7 in dendritic cells. Journal of immunology (Baltimore, Md. : 1950), 176(9), 5153-5159. https://doi.org/10.4049/jimmunol.176.9.5153

7. Rizeq, B., & Malki, M. I. (2020). The Role of CCL21/CCR7 Chemokine Axis in Breast Cancer Progression. Cancers, 12(4), 1036. https://doi.org/10.3390/cancers12041036

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CCR7 Antibody (NBP2-67324)(2)

Publications using NBP2-67324

• Zhang D, Chen Q, Bi Y et al. Bio-inspired poly-DL-serine materials resist the foreign-body response Nature communications 2021-09-07 [PMID: 34493717] (IF/IHC, Mouse)
• Kaya P, Lee SR, Lee YH et al. Curcumae Radix Extract Decreases Mammary Tumor-Derived Lung Metastasis via Suppression of C-C Chemokine Receptor Type 7 Expression Nutrients 2019-02-15 [PMID: 30781353] (IF/IHC, Mouse)

Bioinformatics

• Gene Symbol: CCR7